Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Malignant Melanoma
Interventions: Peginterferon alfa-2b, Temozolomide, Recombinant interferon alfa-2b; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2031
U.S. locations: 3
States / cities: San Diego, California • Memphis, Tennessee • Houston, Texas

Conditions: Metabolic Syndrome X
Interventions: Freeze-dried Whole Grape Powder, Grape Powder Placebo; Other
Lead sponsor: University of Connecticut; Other
Eligibility: 30 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
Interventions: Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside; Biological · Other
Lead sponsor: CG Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 45
States / cities: Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Respiratory Distress Syndrome In Premature Infants
Interventions: Babylog VN500 in HFOV Mode; Device
Lead sponsor: Draeger Medical Systems, Inc.; Industry
Eligibility: 23 Weeks to 30 Weeks
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 14
States / cities: Little Rock, Arkansas • San Diego, California • Iowa City, Iowa + 9 more

Conditions: Myelodysplastic Syndromes
Interventions: Lenalidomide; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Scottsdale, Arizona • St Louis, Missouri

Conditions: Multiple Myeloma
Interventions: bb2121, Fludarabine, Cyclophosphamide, Lenalidomide; Biological · Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 15 more

Conditions: Higher Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Interventions: AMG 176, Azacitidine; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: High Blood Pressure
Interventions: Yoga exercise program, Blood pressure education/walking program; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ringed Sideroblasts, Secondary Acute Myeloid Leukemia
Interventions: Pretargeted Radioimmunotherapy, Cyclosporine, Mycophenolate Mofetil, Total-Body Irradiation, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Fludarabine Phosphate, Pharmacological Study, Laboratory Biomarker Analysis; Biological · Drug · Radiation + 2 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Low Protein Dietary Intake, High Protein Dietary Intake
Interventions: Meal Patterning; Other
Lead sponsor: Purdue University; Other
Eligibility: 21 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Pre-Exposure Prophylaxis (PrEP), Breast Feeding
Interventions: Cabotegravir Injection [Apretude]; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lung Cancer
Interventions: Six-Minute Walk Test, Exercise stress test; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections, HIV Wasting Syndrome
Interventions: Optimune oral nutritional supplement; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 18
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 12 more

Conditions: Anaplastic Astrocytoma, Anaplastic Ependymoma, Astrocytoma, Grade II, Ependymoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma, Brainstem Tumors
Interventions: imetelstat sodium; Drug
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: 12 Months to 21 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 11
States / cities: Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more

Conditions: Adult Acute Lymphoblastic Leukemia in Remission, Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions: nonmyeloablative allogeneic hematopoietic stem cell transplantation, donor lymphocytes, cyclosporine, total-body irradiation, fludarabine phosphate, mycophenolate mofetil, laboratory biomarker analysis, peripheral blood stem cell transplantation; Procedure · Biological · Drug + 2 more
Lead sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; Other
Eligibility: Up to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 3
States / cities: Portland, Oregon • Seattle, Washington

Conditions: Dietary Fats, Pharmacokinetics
Interventions: Regorafenib (Stivarga, BAY73-4506); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Brighton, Massachusetts

Conditions: Barrett's Esophagus, CIS, High Grade Dysplasia
Interventions: HPPH; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Head and Neck Cancer
Interventions: ConformalFLASH irradiation; Radiation
Lead sponsor: IBA Proton Therapy, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Multiple Myeloma
Interventions: Lenalidomide Induction, Sequential Maintenance Therapy; Drug
Lead sponsor: Cristina Gasparetto; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Multiple Myeloma
Interventions: high dose chemotherapy then autologous hematopoietic cell transplant; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Feeding Difficulties, Aspiration, Gastrostomy
Interventions: amino acid based formula (e.g. Elecare Jr), low bile acid binding blenderized diet (e.g. Kate Farms), high bile acid binding blenderized diet; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 5 Years to 21 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Aging
Interventions: High-Intensity Interval Training (HIIT) Breaks to Sitting, Light-Intensity Interval Training (LIIT) Breaks to Sitting; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 40 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: PROSTATE CANCER, NERVES, NEUROBIOLOGY OF CANCER, NEUROLYSIS
Interventions: Periprostatic neurolysis with dehydrated alcohol (ethanol); Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV Infections, Cervix, Dysplasia
Interventions: Fluorouracil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 19
States / cities: Los Angeles, California • Miami, Florida • Chicago, Illinois + 13 more

Search by objective public record fields.

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Effects of a Standardized Freeze-dried Grape Powder on High Density Lipoprotein (HDL) Function in Metabolic Syndrome

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Safety and Efficacy Study of the Draeger Babylog VN500 Device in HFOV Mode in VLBW Neonates

Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

Lifestyle Modification and Blood Pressure Study

Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

The Body's Response to Changes in Dietary Protein and Meal-Frequency In Men

Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana

Six-Minute Walk Test in Patients at High Risk for Complications From Lung Resection

A Study to Evaluate High Protein Supplementation in HIV-Positive Patients With Stable Weight Loss

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission

The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib

Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus

A Pilot Study of Ultra-High Dose Rate (ConformalFLASH®), for Reirradiation of Carcinoma of the Head and Neck

Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy

High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma

The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 1)

Breaking Sitting with High-intensity Interval Training for Brain Health

Periprostatic Neurolysis in Prostate Cancer

A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women